SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

24 Jul 2025 Evaluate
The revenue slipped marginally during the June 2025 quarter. A decline of about Rs. 3925.30 millions was observed as compared to Rs. 4014.30 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2025 is Rs. -280.60 millions as compared to Net Profit of Rs. 149.50 millions of corresponding quarter ended June 2024Operating profit for the quarter ended June 2025 decreased to 204.10 millions as compared to 550.90 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 3925.30 4014.30 -2.22 3925.30 4014.30 -2.22 15181.90 17908.10 -15.22
Other Income 55.80 35.20 58.52 55.80 35.20 58.52 184.80 85.10 117.16
PBIDT 204.10 550.90 -62.95 204.10 550.90 -62.95 1465.20 2664.90 -45.02
Interest 236.10 118.80 98.74 236.10 118.80 98.74 566.30 368.20 53.80
PBDT -32.00 432.10 -107.41 -32.00 432.10 -107.41 908.80 2412.00 -62.32
Depreciation 252.00 237.00 6.33 252.00 237.00 6.33 982.50 879.80 11.67
PBT -284.00 195.10 -245.57 -284.00 195.10 -245.57 -73.70 1532.20 -104.81
TAX -3.40 45.60 -107.46 -3.40 45.60 -107.46 13.60 365.80 -96.28
Deferred Tax -3.40 -1.70 100.00 -3.40 -1.70 100.00 13.60 38.10 -64.30
PAT -280.60 149.50 -287.69 -280.60 149.50 -287.69 -87.30 1166.40 -107.48
Equity 184.50 184.40 0.05 184.50 184.40 0.05 184.50 184.40 0.05
PBIDTM(%) 5.20 13.72 -62.11 5.20 13.72 -62.11 9.65 14.88 -35.15

Indoco Remedies Share Price

221.30 -6.90 (-3.02%)
11-May-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1290.10
Cipla 1309.20
Zydus Lifesciences 953.80
Lupin 2280.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×